Director/PDMR Shareholding

RNS Number : 2933L

GlaxoSmithKline PLC

17 July 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 70.538 (personal contribution) £16.18 174.682 (personal contribution) £16.18 190.188 (personal contribution) £16.18 70.538(personal contribution) £16.18 174.669 (personal contribution) £16.18 190.176 (personal contribution) £16.18 70.538 (matching shares) £16.18 174.682 (matching shares) £16.18 190.188 (matching shares) £16.18 70.538 (matching shares) £16.18 174.669 (matching shares) £16.18 190.176 (matching shares)
d)	Aggregated information Aggregated volume Price	1,741.582 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 51.658 (personal contribution) £16.18 118.682 (personal contribution) £16.18 99.029 (personal contribution) £16.18 51.658 (personal contribution) £16.18 99.017 (personal contribution) £16.18 51.658 (matching shares) £16.18 118.682 (matching shares) £16.18 99.029 (matching shares) £16.18 51.658 (matching shares) £16.18 99.017 (matching contribution)
d)	Aggregated information Aggregated volume Price	840.088 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Debruyne
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 166.446 (personal contribution) £16.18 166.433 (personal contribution) £16.18 166.446 (matching shares) £16.18 166.433 (matching shares)
d)	Aggregated information Aggregated volume Price	665.758 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 98.527 (personal contribution) £16.18 230.682 (personal contribution) £16.18 172.780 personal contribution) £16.18 98.514 (personal contribution) £16.18 230.669 (personal contribution) £16.18 172.780 (personal contribution) £16.18 98.527 (matching shares) £16.18 230.682 (matching shares) £16.18 172.780 (matching shares) £16.18 98.514 (matching shares) £16.18 230.669 (matching shares) £16.18 172.780 (matching shares)
d)	Aggregated information Aggregated volume Price	2,007.904 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 36.169 (personal contribution) £16.18 85.292 (personal contribution) £16.18 62.593 (personal contribution) £16.18 36.169 (personal contribution) £16.18 85.292 (personal contribution) £16.18 62.582 (personal contribution) £16.18 36.169 (matching shares) £16.18 85.292 (matching shares) £16.18 62.593 (matching shares) £16.18 36.169 (matching shares) £16.18 85.292 (matching shares) £16.18 62.582 (matching shares)
d)	Aggregated information Aggregated volume Price	736.194 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S A Hussain
b)	Position/status	President, Global Pharmaceuticals
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 170.501 (personal contribution) £16.18 201.553 (personal contribution) £16.18 173.006 personal contribution) £16.18 201.553 (personal contribution) £16.18 172.994 (personal contribution) £16.18 170.501 (matching shares) £16.18 201.553 (matching shares) £16.18 173.006 (matching shares) £16.18 201.553 (matching shares) £16.18 172.994 (matching shares)
d)	Aggregated information Aggregated volume Price	1,839.214 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $42.50 70.929 (personal contribution) $42.50 70.929 (matching shares)
d)	Aggregated information Aggregated volume Price	141.858 $42.50
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 57.960 (personal contribution) £16.18 108.550 (personal contribution) £16.18 78.775 (personal contribution) £16.18 57.960 (personal contribution) £16.18 108.550 (personal contribution) £16.18 78.763 (personal contribution) £16.18 57.960 (matching shares) £16.18 108.550 (matching shares) £16.18 78.775 (matching shares) £16.18 57.960 (matching shares) £16.18 108.550 (matching shares) £16.18 78.763 (matching shares)
d)	Aggregated information Aggregated volume Price	981.116 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 78.015 (personal contribution) £16.18 158.805 (personal contribution) £16.18 118.568 (personal contribution) £16.18 78.002 (personal contribution) £16.18 158.805 (personal contribution) £16.18 118.568 (personal contribution) £16.18 78.015 (matching shares) £16.18 158.805 (matching shares) £16.18 118.568 (matching shares) £16.18 78.002 (matching shares) £16.18 158.805 (matching shares) £16.18 118.568 (matching shares)
d)	Aggregated information Aggregated volume Price	1,421.526 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 52.988 (personal contribution) £16.18 97.162 (personal contribution) £16.18 74.644 (personal contribution) £16.18 52.988 (matching shares) £16.18 97.162 (matching shares) £16.18 74.644 matching shares)
d)	Aggregated information Aggregated volume Price	449.588 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D E Troy
b)	Position/status	SVP & General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $42.50 40.363 (personal contribution) $42.50 90.880 (personal contribution) $42.50 75.270 (personal contribution) $42.50 40.363 (personal contribution) $42.50 90.880 (personal contribution) $42.50 75.258 (personal contribution) $42.50 40.363 (matching shares) $42.50 90.880  (matching shares) $42.50 75.270  (matching shares) $42.50 40.363  (matching shares) $42.50 90.880  (matching shares) $42.50 75.258 (matching shares)
d)	Aggregated information Aggregated volume Price	826.028 $42.50
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P J T Vallance
b)	Position/status	President, R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.18 114.838 (personal contribution) £16.18 186.805 (personal contribution) £16.18 128.784 (personal contribution) £16.18 114.838 (personal contribution) £16.18 186.805 (personal contribution) £16.18 128.784 (personal contribution) £16.18 114.838 (matching shares) £16.18 186.805 (matching shares) £16.18 128.784 (matching shares) £16.18 114.838 (matching shares) £16.18 186.805 (matching shares) £16.18 128.784 (matching shares)
d)	Aggregated information Aggregated volume Price	1,721.708 £16.18
e)	Date of the transaction	2017-07-14
f)	Place of the transaction	n/a

 

END

 

 

DSHEDLFFDDFXBBE